(Q113887340)

English

Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis (English)

0 references

0 references

0 references

10 July 2019

0 references

end time

August 2020

0 references

number of participants

110

0 references

research intervention

immunologic factor

0 references

methotrexate

0 references

tofacitinib

0 references

Abortifacient Agents, Nonsteroidal

0 references

reproductive control agents

0 references

antineoplastic antimetabolite

0 references

antimetabolite

0 references

mechanism of action

0 references

alkylating antineoplastic agent

0 references

dermatologic drug

0 references

enzyme inhibitor

0 references

folic acid antagonists

0 references

immunosuppressive drug

0 references

disease-modifying antirheumatic drug

0 references

DNA polymerase inhibitors

0 references

protein kinase inhibitors

0 references

clinical trial phase

phase IV clinical trial

0 references

research subject recruitment status

unknown

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT04464642

0 references

(Q113887340)

Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)